Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 6/20 | 0.44 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.35 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468349 | 1.00 | BCHE (0.44) | BCHESLC6A9SRD5A1SRD5A2KIF11 | |
| Hydrochloric Acid SCHEMBL6167375 | 0.99 | BCHE (0.44) | BCHESLC6A9SRD5A1SRD5A2KIF11 | |
| Hydrochloric Acid SCHEMBL6167370 | 0.99 | BCHE (0.44) | BCHESLC6A9SRD5A1SRD5A2KIF11 | |
| SCHEMBL5709385 | 0.95 | BCHE (0.42) | BCHESLC6A9SRD5A1SRD5A2 | |
| SCHEMBL5709469 | 0.95 | BCHE (0.42) | BCHESLC6A9SRD5A1SRD5A2 | |
| SCHEMBL5709440 | 0.92 | BCHE (0.41) | BCHESLC6A9KIF11UTS2R | |
| SCHEMBL5709434 | 0.92 | BCHE (0.41) | BCHESLC6A9KIF11UTS2R | |
| SCHEMBL5709486 | 0.92 | BCHE (0.41) | BCHESLC6A9KIF11UTS2R | |
| SCHEMBL5709489 | 0.92 | BCHE (0.41) | BCHESLC6A9KIF11UTS2R | |
| SCHEMBL5709407 | 0.89 | BCHE (0.39) | BCHESLC6A9KIF11KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009018368-A1 | COMBINATION TREATMENT OF NMDA (N-METHYL-D-ASPARTATE)-ENHANCER, GLYCINE TRANSPORTER INHIBITOR, D-AMINO ACID OXIDASE INHIBITOR (DAAOI) FOR NEUROPSYCHIATRIC DISORDERS | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2009-02-05 | — | — | WO | claimed |
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | H. LUNDBECK A/S (DK) | 2006-10-05 | — | — | US | claimed |
| EP-1660130-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. Lundbeck A/S (DK) | 2006-05-31 | — | — | EP | claimed |
| EP-1301502-B1 | COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | LUNDBECK & CO AS H (DK) | 2005-05-18 | — | — | EP | claimed |
| WO-2005018676-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. LUNDBECK A/S (DK) | 2005-03-03 | — | — | WO | claimed |
| US-11529342-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2022-12-20 | — | — | US | disclosed |
| EP-3006023-B1 | SORBIC ACID AND DERIVATIVES THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151301-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2019-05-23 | — | — | US | disclosed |
| EP-3006024-B1 | BENZOIC ACID OR SALTS THEREOF TO ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RES INST HARBOR UCLA MEDICAL CT (US) | 2019-03-20 | — | — | EP | disclosed |
| US-10149845-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-12-11 | — | — | US | disclosed |
| US-10039730-B2 | Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2018-08-07 | — | — | US | disclosed |
| US-20170189358-A1 | SORBIC AND BENZOIC ACID AND DERIVATIVES THEREOF ENHANCE THE ACTIVITY OF A NEUROPHARMACEUTICAL | LOS ANGELES BIOMEDICAL RESEARCH INSTITUTE AT HARBOR-UCLA MEDICAL CENTER (US) | 2017-07-06 | — | — | US | disclosed |
| WO-2005018676-A1 | THE COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND A GLYCINE TRANSPORTER TYPE 1 INHIBITOR FOR THE TREATMENT OF DEPRESSION | H. LUNDBECK A/S (DK) | 2005-03-03 | — | — | WO | disclosed |
| US-20040106975-A1 | Rail stent | GMP/CARDIAC CARE, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004045474-A1 | RAIL STENT | GMP CARDIAC CARE, INC. (US) | 2004-06-03 | — | — | WO | disclosed |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | PHARMACIA CORPORATION | 2004-04-01 | — | — | US | disclosed |
| WO-2003101380-A2 | AMYOTROPHIC LATERAL SCLEROSIS TREATMENT WITH CYCLOOXYGENASE-2 INHIBITORS | PHARMACIA CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
| US-20030181445-A1 | Novel compounds and their use as glycine transport inhibitors | H. LUNDBECK A/S (DK) | 2003-09-25 | — | — | US | disclosed |
| EP-1301502-A1 | NOVEL COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | H. Lundbeck A/S (DK) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002008216-A1 | NOVEL COMPOUNDS AND THEIR USE AS GLYCINE TRANSPORT INHIBITORS | H. LUNDBECK A/S (DK) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181445-A1 | Novel compounds and their use as glycine transport inhibitors | SLC1A5, SLC7A1, SLC7A11 | BCHE 2384/4885SLC6A9 12/4885SRD5A1 1686/4885 |
| US-20060223857-A1 | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | SLC6A4, SLC6A7, SLC6A5 | BCHE 2957/4885SLC6A9 14/4885SRD5A1 1011/4885 |
| US-20040063751-A1 | Combination therapy for the treatment of amyotrophic lateral sclerosis (ALS) with cyclooxygenase-2 (COX-2) inhibitor(s) and a second drug | SMN1; SMN2, PTGS2, PTGES2 | BCHE 169/4885SLC6A9 227/4885SRD5A1 1570/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.